Founded in 2008, Alteogen is a leading biotechnology company with a robust pipeline
that includes next-generation biobetters with improved efficacy in comparison
with existing biologics and biosimilars with its proprietary platform technology.

Alteogen is focused on the cutting-edge areas of the industry,
long-acting biobetters, proprietary antibody-drug conjugate, and monoclonal antibody biosimilars.

Currently, Alteogen has developed NexP™ Fusion Technology, a next-generation long-acting bio-better technology, NexMab™ ADC Technology, an antibody-drug conjugate technology, novel human recombinant hyaluronidase based on Hybrozyme™ Technology enabling large volume IV infusions to subcutaneous injections, and is jointly developing monoclonal antibody biosimilars with overseas strategic alliance partners.